Proteins encoded by Polycomb and Trithorax-group (Pc-G and Trx-G) genes regulate developmental fates by maintaining or repressing HOX gene expression, respectively. In a search for candidate myeloid leukemia tumor suppressor genes from a *2.5 Mb commonly-deleted segment within chromosome band 7q22, we identified a novel human Trithorax (Trx) family member named MLL5. Trx-G genes encode proteins that modulate transcriptional programs through protein -protein interactions that are mediated by PHD and SET domains, and by binding to DNA via A-T hooks and methyltransferase homology motifs. MLL5 is a homolog of the Drosophila gene CG9007; it encodes a 6.5 kb mRNA that is expressed widely. MLL5 includes a SET domain and a single PHD finger, but lacks A-T hooks and methyltransferase homology domains that are found in MLL. The leukemia cell line RCV-ACV-A carries a heterozygous missense mutation within the PHD domain; however, no mutations within the MLL5 coding region were detected in primary leukemias. MLL5 is a novel mammalian Trx-G gene that might modulate transcription by protein association.
Proteins encoded by Polycomb and Trithorax-group (Pc-G and Trx-G) genes regulate developmental fates by maintaining or repressing HOX gene expression, respectively. In a search for candidate myeloid leukemia tumor suppressor genes from a *2.5 Mb commonly-deleted segment within chromosome band 7q22, we identified a novel human Trithorax (Trx) family member named MLL5. Trx-G genes encode proteins that modulate transcriptional programs through protein -protein interactions that are mediated by PHD and SET domains, and by binding to DNA via A-T hooks and methyltransferase homology motifs. MLL5 is a homolog of the Drosophila gene CG9007; it encodes a 6.5 kb mRNA that is expressed widely. MLL5 includes a SET domain and a single PHD finger, but lacks A-T hooks and methyltransferase homology domains that are found in MLL. The leukemia cell line RCV-ACV-A carries a heterozygous missense mutation within the PHD domain; however, no mutations within the MLL5 coding region were detected in primary leukemias. MLL5 is a novel mammalian Trx-G gene that might modulate transcription by protein association. Oncogene (2002 Oncogene ( ) 21, 4849 -4854. doi:10.1038 Keywords: monosomy 7; deletion 7q; myeloid leukemia; trithorax genes Tumorigenesis involves cooperating genetic lesions that disable tumor suppressor genes (TSGs) and activate proto-oncogenes (Hanahan and Weinberg, 2000) . The proteins encoded by TSGs and proto-oncogenes impinge on the same fundamental processes such as cell division, survival, and transcription (Hanahan and Weinberg, 2000) . Many of the recurring chromosomal translocations found in myeloid malignancies perturb transcription by deregulating gene expression or by producing aberrant fusion proteins (Look, 1997) . Tissue culture experiments and observations in mouse models underscore the central role of mis-regulated transcription in leukemogenesis (Look, 1997; Rowley, 1999) . This prominent involvement of transcription factors that function as dominant (or as dominant negative) oncoproteins infers that mutations in TSGs that regulate transcription might also contribute to leukemia.
Loss of an entire chromosome 7 homolog (monosomy 7) or a deletion of the long arm of this chromosome (del(7q)) are among the most common recurring cytogenetic aberrations detected in myeloid malignancies. Monosomy 7 and del(7q) occur in a variety of clinical contexts including de novo myelodysplastic syndrome and acute myeloid leukemia (MDS and AML), leukemias associated with a constitutional predisposition, and therapy-related MDS or AML (Luna-Fineman et al., 1995) . A commonly deleted segment (CDS) in chromosome band 7q22 bounded by the genetic markers D7S1503 and D7S1841 was defined by analysing leukemia samples with abnormalities of 7q (Kratz et al., 2001; Le Beau et al., 1996) . A bacterial and P1 artificial chromosome (BAC and PAC) contig spanning most of this interval (Kratz et al., 2001 ) served as a starting point for identifying a novel Trx gene called MLL5, which is related to the human MLL gene (also known as ALL1, HRX, and Htrx). Recurring translocations involving chromosome band 11q23 fuse MLL with 430 partner genes in AML; these rearrangements result in the production of chimeric fusion proteins that deregulate hematopoietic growth in vitro and in vivo (Canaani et al., 1995; Corral et al., 1996; Dimartino and Cleary, 1999; Dobson et al., 1999; Lavau et al., 2000) . Here we report the cDNA sequence and genomic structure of MLL5, expression in normal and malignant hematopoietic cells, and a comprehensive screen of leukemia samples for mutations and for altered expression.
A 1.8 kb fragment corresponding to the hypothetical gene HDCMC04P was generated by performing reverse transcriptase polymerae chain reaction (RT -PCR) on bone marrow. This fragment hybridized to a *6.5 kb RNA on Northern blots prepared from hematopoietic tissues (Figure 1a) . A *1.5 kb band of reduced intensity was also seen in lanes containing abundant MLL5 transcript (data not shown). Expression was detected in all tissues analysed on RNA tissue arrays, with the highest levels found in fetal thymus and kidney and in adult hematopoietic tissues, jejunum, and cerebellum (Figure 1b) . The full-length MLL5 transcript was assembled by a combination of bioinformatic analysis to discover putative exons followed by amplification and sequencing of PCR products, and by identifying and sequencing EST clones corresponding to 3' segments of the gene. Once the 5' and 3' ends of the gene were known, a cDNA encoding the entire 5574 bp open reading frame was amplified from normal bone marrow. Intron/exon boundaries were defined by comparing cDNA and genomic sequences from BAC clones RP11-325F22, CTB-114B19, and CTB-152G17 (Figure 2 ). MLL5 contains 25 exons, and spans 73 kb of genomic DNA. The complete cDNA and amino acid sequences have been deposited in GenBank (Accession number AF519459).
Vertebrate and Drosophila trithorax group (Trx-G) genes encode transcriptional regulators that contain variable numbers of PHD fingers and a SET domain, which mediate protein-protein interactions (Gould, 1997; van Lohuizen, 1999) . MLL5 is a homolog of Drosophila CG9007. Both genes encode a single PHD finger at the amino end that is separated from the SET domain by approximately 180 amino acids (Figure 3a) . Over its entire length, MLL5 is 29% identical and 40% similar to CG9007 with the highest degree of homology observed within the PHD finger (80% identical and 88% similar to CG9007) and lower homology within the SET domain (38% identical and 47% similar) (Figure 3b and c). The mouse cDNA clone MNCb-0467 (GenBank accession ABO41558), which encodes a 5' segment of the murine homolog, is 91% identical to MLL5 over 34% of the complete human cDNA sequence. MLL5 is related to other vertebrate and Drosophila trithorax family members including MLL (Figure 3b and c) . MLL contains three closely spaced PHD domains, a bromodomain, and a C-terminal SET domain (Figure 3c ). The A-T hooks and MT homology domains of MLL, which interact with DNA, are invariably retained in leukemia-associated fusions and are essential for the full transforming ability of MLL fusion genes (Slany et al., 1998; Zeleznik-Le et al., 1994) . Importantly, MLL5 and CG9007 contain neither A-T hooks nor a MT homology domain. MLL5 is 38% identical and 51% similar to MLL over its entire length (Figure 3b ). MLL5 is more distantly related to the human ALR and huASH1 genes and to Drosophila ASH1 (Figure 3a -c) .
The cell lines UoC-M1 and RCV-ACV-A were used to develop conditions for analysing leukemia cells for mutations by single-strand conformation polymorphism analysis (SSCP) and a coupled in vitro transcription/translation (IVTT) procedure to detect mutations that lead to truncated proteins. UoC-M1 was derived from a patient with AML, and shows complex cytogenetic abnormalities including monosomy 7, loss of 5q, and over-expression of MLL (Allen et al., 1998) . Interestingly, the RCV-ACV-A line, which was cultured from a patient with B cell lineage ALL associated with a t(1;19), showed a T to C sequence variation at nucleotide 599 within the PHD domain of the MLL5 cDNA that substitutes a semi-conserved isoleucine residue for threonine (Figure 4 ). This is unlikely to represent a polymporhism as it was not detected in 80 chromosomes from 40 unrelated individuals. RCV-ACV-A cells also express the normal MLL5 transcript (data not shown).
SSCP was performed to analyse MLL5 exons 1 -13, which encode the PHD and SET domains, for mutations in 53 leukemia samples from patients with MDS or AML associated with monosomy 7 or del(7q). Twentyfour were also screened for mutations in exons 14 -24.
In additional studies, a 1.8 kb fragment containing the PHD finger and SET domain was amplified from 33 leukemias characterized by monosomy 7 and tested by IVTT to detect mutations resulting in truncated peptides. Exon 25 (*1.5 kb) was also analysed by IVTT. No mutations were detected in these experiments. Based on the finding of an amino acid substitution within the PHD domain of the t(1;19) cell line, we also investigated 24 primary ALL bone marrows (including 10 samples with a t(1;19)) but detected no other MLL5 mutations. Finally, to ascertain if somatic heterozygous point mutations might contribute to leukemogenesis, samples from 27 children with juvenile myelomonocytic leukemia (JMML) without monosomy 7 were screened for MLL5 point mutations in exons 1 -13. This disorder was selected because a substantial proportion of JMML patients have monosomy 7 at diagnosis, while others develop abnormalities of chromosome 7 with progression (Kaneko et al., 1989; . We found no alterations in MLL5 in any of the JMML bone marrows.
A real-time quantitative PCR assay was developed to evaluate the possibility that MLL5 might be silenced by epigenetic mechanisms in myeloid leukemia as reported for other human TSGs (Baylin et al., 2000) . MLL5 levels in normal bone marrow cells fell within a narrow range (DCT 5.03+0.3 relative to a GAPDH standard). All 26 monosomy 7 leukemia samples from which adequate RNA was available for analysis showed expression levels that were within twofold of normal.
Drosophila and vertebrate HOX genes control developmental programs related to cell identity, segmentation, and body pattern formation (Gould, 1997; van Lohuizen, 1999) . HOX genes are precisely regulated during hematopoietic differentiation, with decreased expression generally associated with maturation and lineage commitment (Lawrence and Largman, 1992; Lessard et al., 1998) . Consistent with their function as HOX repressors, Pc-G genes are expressed at low levels in immature subpopulations of hematopoietic cells, and at higher levels in more differentiated cells (Lessard et al., 1998) . Mis-expression and rearrangements of HOX genes have been reported in murine and human leukemias. For example, proviral integrations deregulate Hoxa7 and Hoxa9 expression in leukemias arising in BXH-2 mice, and HOXA9 is fused to the nucleoporin NUP98 in a subset of human AMLs (Borrow et al., 1996; Nakamura et al., 1996a,b) . Indeed, it has been suggested that aberrant HOX gene expression might represent a common underlying molecular consequence of leukemia-associated genetic lesions (Look, 1997) .
MLL5 encodes a novel Trx-G protein with interesting structural elements. It has a single PHD domain, and the SET domain is located in the central region of the protein rather that at the carboxy end (Figure 3a) . The A-T hooks domain of MLL, which mediate DNA binding, is invariably retained in leukemia-associated fusions (Canaani et al., 1995; Dimartino and Cleary, 1999; Slany et al., 1998; Zeleznik-Le et al., 1994) . The absence of either A-T hooks or of an MT homology domain in the MLL5 protein suggests that it might not bind DNA, but may instead modulate transcription indirectly via protein -protein interactions through the PHD and SET domains. Consistent with this idea, human and Drosophila Trx-G protein self-associate, and TRITHORAX and ASH1 interact through their SET domains (Rozovskaia et al., 1999 (Rozovskaia et al., , 2000 . Figure 2 Structure of MLL5. MLL5 is contained within the BAC clones RP11325F22, CTB-114B19, and CTB-152G17. Intron/ exon boundaries were determined by comparing cDNA and genomic sequences. Materials and methods: Genomic sequences generated from the 7q22 CDS were used to perform BLAST searches. These queries identified HDCMO4P (GenBank accession AF067804). To clone the full-length MLL5 cDNA, the GRAIL program was used to predict additional exons that were subsequently confirmed by performing RT -PCR experiments with one oligonucleotide from the known cDNA sequence and another from the putative exon(s). The output was assembled using the Macvector and AssemblyLIGN programs
We did not uncover inactivating mutations or decreased expression of MLL5 in leukemia samples. The significance of the heterozygous alteration detected in RCV-ACV-A cells is unknown as the primary leukemia and normal tissues were not available from the patient from whom this line was derived. However, this mutation affects a semi-conserved residue within the PHD domain and was not detected in 80 normal chromosomes. This suggests that it is not a simple polymorphism, but may have functional consequences.
The 7q22 CDS might harbor another myeloid TSG; this possibility can only be fully evaluated by cloning and testing additional candidate genes. Alternatively, it is possible that inactivation of one allele of MLL5 (or of MLL5 and another gene located within the deleted interval) contributes to leukemogenesis by haploinsufficiency. Interestingly, germline mutations of RUNX1 (also known as AML1 or CBFA2) were recently found to cause a familial platelet disorder that is associated with a predisposition to myeloid leukemia (Song et al., 1999) . Mutational analysis of leukemias from affected individuals showed no evidence for inactivation of the normal RUNX1 allele, suggesting that reducing the concentration of this myeloid transcription factor contributes to leukemogenesis.
Given the complex interactions between Trx-G proteins, Pc-G proteins and other components of the chromatin remodeling and transcriptional machinery, dosage effects of MLL5 on cell growth are plausible. Heterozygous Mll mutant mice are anemic and show reduced platelet counts; in addition, fetal liver and marrow cells from these mice form fewer and smaller myeloid progenitor colonies than controls (Yagi et al., 1998; Yu et al., 1995) . Haploinsufficiency for either Mll or Bmi1 induced skeletal transformations, which were partially corrected when these mutant strains were intercrossed (Hanson et al., 1999) . Transgenic mice that over-express Bmi1 exhibit a high incidence of Conserved residues are shown in black and semi-conserved residues are shown in gray lymphomas (Alkema et al., 1997) . Given the importance of Pc-G and Trx-G protein levels in specifying cell fates and for growth control, haploinsufficiency for MLL5 might contribute to leukemogenesis in the context of other inherited or somatic genetic lesions. This idea is consistent with data showing that monosomy 7 and del(7q) are frequently detected in clones with other genetic lesions (e.g. mutations in genes that predispose to leukemia, RAS mutations, or complex cytogenetic abnormalities) (Le Beau et al., 1986; Luna-Fineman et al., 1995; Thirman and Larson, 1996) .
Murine gene targeting approaches have proven highly informative for elucidating the functions of mammalian Trx-G and Pc-G group genes in development and hematopoiesis. Based on this experience, we are generating a line of mutant mice to clarify the normal functions of MLL5 and to explore its potential role in leukemia. The wild-type sequence is shown at the top, and the T-to-C change at nucleotide 599 detected in RCV-ACV-A is shown below. This substitutes threonine for a semi-conserved isoleucine residue in the PHD domain. (b) The sequence variation found in RCV-ACV-A cells eliminates a recognition site for the restriction enzyme Mbo1. DNA from normal bone marrow and RCV-ACV-A was amplified using oligonucleotide primers specific from exon 4 of MLL5 and digested with Mbo1. Note that the RCV-ACV-A cell line retains a normal MLL5 allele. Materials and methods: Patient samples and leukemia cell lines were analysed for mutations using a combination of Southern blot analysis, SSCP, and IVTT using procedures that we have described previously (Kalra et al., 1994; Side et al., 1997) . MLL5 expression was assayed by quantitative realtime PCR. Primer Express software (PE Applied Biosystems, Foster City, CA, USA) was used to design the following primers for amplifying MLL5 and probe for TaqMan hybridization: forward (5'-TTATATACCAGCAGCTCACATCATTCA-3'), reverse (5'-CATTTTTGCTAATAAGGACTGATGGA-3'), probe (5'-FAM-ACATTGGTTTGCCCTATGCGGACCATAAT-TAMARA-3'). Samples were amplified in an ABI PRISM TM 7700 Sequence Detection System at the following cycle parameters: 508 for 2 min, 958 for 10 min, followed by 40 cycles of 958 for 15 s and 608C for 1 min
